We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00879619
Recruitment Status : Terminated (Terminated due to slow accrual.)
First Posted : April 10, 2009
Results First Posted : June 6, 2013
Last Update Posted : February 1, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

April 8, 2009
April 10, 2009
April 19, 2013
June 6, 2013
February 1, 2017
July 2009
October 2011   (Final data collection date for primary outcome measure)
Prostate Specific Antigen (PSA) Response Rate [ Time Frame: Baseline, every 3 weeks, at study termination, and then for 3 years ]
Defined by >= 30% decline in PSA from baseline for at least 3 months during study entry. Response rates will be expressed with two-sided exact binomial confidence intervals. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
PSA response defined by >30% decrease in PSA from baseline for at least 3 months during study therapy. [ Time Frame: 6 years ]
Complete list of historical versions of study NCT00879619 on ClinicalTrials.gov Archive Site
  • Rates of Tumor Response (ORR) [ Time Frame: Every 2 months ]
    Response rates will be expressed with two-sided exact binomial confidence intervals. The difference of response rates between different pre-treatment pathological stages or Gleason scores will also be examined by Fisher's exact test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
  • Duration of Response (DR) [ Time Frame: Up to 3 years ]
    Response rates will be expressed with two-sided exact binomial confidence intervals.
  • Time to Progression (TTP) by PSA Response and Disease Response [ Time Frame: Baseline, every 3 weeks, at study termination, and then for 3 years ]
    Defined as an absolute increase in PSA of at least 2 ng/ml. For subjects with measurable disease, Response Evaluation Criteria In Solid Tumors (RECIST) criteria will be used. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. Associations between PSA response and tumor response will also be examined by Fisher's exact test.
  • Survival [ Time Frame: At 2 and 3 years ]
    Quantitative Kaplan-Meyer estimates of progression-free survival and overall survival will be determined.
  • Qualitative and Quantitative Toxicity [ Time Frame: Every 3 weeks and at study termination ]
    Severity will be categorized by toxicity grade according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Categorical analysis of toxicities will be performed.
  • Objective response rate (ORR) [ Time Frame: 6 years ]
  • Duration of Response (DR) [ Time Frame: 6 years ]
  • Time to Progression (TTP) by PSA Response and Disease Response [ Time Frame: 6 years ]
  • Two and three year survival [ Time Frame: 6 years ]
  • Qualitative and Quantitative Toxicity [ Time Frame: 6 years ]
Not Provided
Not Provided
 
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel and prednisone together with sunitinib malate may kill more tumor cells.

PURPOSE: This pilot phase I/II trial studies the side effects and best way to give docetaxel and prednisone together with sunitinib malate and to see how well it works in treating patients with prostate cancer that progressed after hormone therapy.

PRIMARY OBJECTIVES:

I. To evaluate the response by prostate specific antigen (PSA) of docetaxel/prednisone plus sunitinib (sunitinib malate) in chemotherapy-naive, hormone refractory prostate cancer subjects with biochemical relapse.

SECONDARY OBJECTIVES:

I. To determine the objective response rate (ORR) and duration of response (DR) in subjects with measurable disease.

II. To determine overall survival (OS) and time to progression (TTP). III. To evaluate the safety and tolerability of sunitinib in combination with docetaxel and prednisone.

OUTLINE:

Patients receive docetaxel intravenously (IV) over 60 minutes on day 1, prednisone orally (PO) twice daily (BID) on days 1-21, and sunitinib malate PO once daily (QD) on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for 3 years.

Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Prostate Cancer
  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer
  • Stage I Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer
  • Drug: sunitinib malate
    Given PO
    Other Names:
    • SU11248
    • sunitinib
  • Drug: docetaxel
    Given IV
    Other Name: TXT
  • Drug: prednisone
    Given PO
    Other Names:
    • Delta(1)-Cortisone
    • deltacortisone
    • deltadehydrocortisone
    • metacortandracin
    • PRD
    • PRED
Experimental: Chemotherapy and enzyme inhibitor
Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: sunitinib malate
  • Drug: docetaxel
  • Drug: prednisone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
4
November 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Subjects must have a histological diagnosis of adenocarcinoma of the prostate
  • Age ≥ 18
  • Subjects must have metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy by one or more of the following (despite androgen deprivation and anti-androgen withdrawal when applicable) check all that apply.
  • Subjects may have received prior surgery. However, at least 21 days must have elapsed since completion of surgery and Subject must have recovered from all side effects.
  • Subjects must have adequate hepatic function as defined by:
  • a serum bilirubin ≤1.5 x the institutional upper limit of normal (IULN),
  • Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) ≤2.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy
  • Subjects must have 2 pre-study PSA > 2ng/ml at least 1 week apart within 28 days prior to start of therapy
  • Subjects must have been surgically or medically castrated. If method of castration is luteinizing hormone-releasing hormone (LHRH) agonist (leuprolide or goserelin), then the Subject should be willing to continue the use of LHRH agonists. Castration using LHRH agonist should not be interrupted and subjects who have stopped treatment should be willing to restart.
  • Subjects must not take vitamins, herbs, or micronutrient supplement within 28 days prior to start of therapy.
  • Prior external beam radiation therapy (to less than 30% of the bone marrow only) is allowed. This includes prior use of samarium, but subjects can not have received prior strontium. At least 28 days must have elapsed since the completion of radiation therapy and the Subject must have recovered from side effects. Soft tissue disease which has been radiated in the prior 2 months is not assessable as measurable disease.
  • Subjects with a history of myocardial infarction are not eligible. Subjects must have a baseline EKG to rule out underlying cardiac disease within 42 days prior to registration. Subjects with a history of cardiac disease, specifically congestive heart failure (CHF) are ineligible unless their disease is well-controlled. Subjects with history of cardiovascular accident (CVA) or atrial fibrillation are ineligible.
  • Subjects with a history of brain metastases or who currently have treated or untreated brain metastases are not eligible. Subjects with clinical evidence of brain metastases must have a brain CT or MRI negative for metastatic disease within 56 days prior to registration.

    *Liver function tests should be evaluated prior to each treatment.

  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Subjects must have an adequate renal function as defined by:
  • a serum creatinine ≤1.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy and a urine protein: creatinine (UPC) ratio of ≤ 1.0.
  • Subjects must have the following hematological criteria (minimal values):
  • Absolute neutrophil count ≥ 1,500/mm³
  • Hemoglobin of ≥ 8.0gm/dL,
  • White blood cell count ≥ 2500,
  • Platelets ≥ 75,000/mm³
  • Subjects must be able to take oral medications

Exclusion Criteria

  • Subjects must not have received chemotherapy, biologic therapy or any other investigational drug for any reason within 28 days prior to start of therapy and must have recovered from toxicities of prior therapy to grade 1 or less with the exception of alopecia.
  • Subjects may not have ongoing problems with bowel obstruction or short bowel syndrome characterized by grade 2 or greater diarrhea or malabsorptive disorders.
  • Men of child bearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
  • Subjects with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 will be excluded
  • Subjects should not have psychological, familial, sociological, or geographical conditions that do not permit medical follow-up or compliance with the study protocol.
  • Subjects should not have any medical life-threatening complications of their malignancies
  • Subjects should not have a known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection, or HIV).
  • Subjects should not have current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
  • Baseline blood pressure of < or equal to 150/100 mmHg. Subjects with a blood pressure reading above this level should be initiated on anti-hypertensive therapy and may be considered for protocol treatment when their blood pressure is adequately controlled.
  • Subjects with New York Heart Association (NYHA) Grade II or greater congestive heart failure are not eligible. Subjects must have a baseline multiple gated acquisition scan (MUGA) or Echocardiogram with a calculated ejection fraction > or equal to 50%.
  • Subjects with clinically significant peripheral vascular disease are not eligible.
  • Subjects with evidence of bleeding diathesis or coagulopathy are not eligible.
  • Subjects with central nervous system or brain metastases are not eligible.
  • Subjects who had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study are not eligible.
  • Subjects with minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0 are not eligible.
  • Subjects with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess are not eligible.
  • Subjects with serious, non-healing wound, ulcer, or bone fracture are not eligible.
  • Subjects who are diagnosed of any other malignancy except non-melanomatous skin cancer in the past 5 years are not eligible.
  • Subjects receiving anticoagulation therapy (e.g. Coumadin) prior to registration are not eligible. Subjects are permitted to have prior Coumadin for prophylaxis against agents that might produce blood clots. Subjects with low dose Aspirin (86mg) are acceptable.
  • Subjects with active thrombophlebitis or hypercoagulability are not eligible. Subjects with known history of pulmonary embolus are not eligible.
  • All Subjects must be informed and must sign and give written informed consent in accordance with institutional and federal guidelines. Subjects who are unable to comply with study and/or follow-up procedures are not eligible.
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00879619
UCI 07-64
2008-6187 ( Other Identifier: University of California, Irvine )
NCI-2010-00216 ( Other Identifier: NCI Clinical Trials Reporting Program (CTRP) )
Yes
Not Provided
Not Provided
John P. Fruehauf, University of California, Irvine
John P. Fruehauf
Sanofi
Principal Investigator: John P Fruehauf, MD, PhD Chao Family Comprehensive Cancer Center
University of California, Irvine
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP